DGAP-News: MeVis Medical Solutions AG english
06.03.08 13:27
abonnierenMeldung
DGAP-News: MeVis Medical Solutions AG english
Alliance
MeVis Research to receive 11 million Euro from federal state of Bremen
Corporate News transmitted by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
------------------------------------
MeVis Research to receive 11 million Euro from federal state of Bremen:
Minority investment of MeVis Medical Solutions in talks with Fraunhofer
Bremen, March 6, 2008.
The Management Board of MeVis Medical Solutions AG
has announced that its R&D partner, the charitable MeVis Research GmbH, is
in talks about a conversion into a Fraunhofer Institute. The accession to
the Fraunhofer-Gesellschaft would allow MeVis Research to double its
research and development activities within just a few years, expand it to
other areas of research and thus increase its attractiveness as an R&D
partner of MeVis Medical Solutions.
The company’s majority shareholder, the federal state of Bremen, yesterday
decided to provide the charitable MeVis Research with additional R&D funds
in an amount of EUR 11 million from the European Fund for Regional
Development. The City has thus paved the way for negotiations with
Fraunhofer-Gesellschaft. If the outcome is positive, MeVis Research, of
which MeVis Medical Solutions currently holds 25.1 percent, would be
admitted to the leading European organisation for applied research. The
additional funds would be used to almost double the number of employees
from today’s 50 in the coming years and to start numerous new research
projects.
As a member of Fraunhofer-Gesellschaft, MeVis Research would have access to
all resources, technologies and networks. Fraunhofer-Gesellschaft has an
annual budget totalling approx. EUR 1.3 billion. The society with its
current 56 organisations is a partner to technology companies and engages
in contractual research in all engineering subjects. From the point of view
of MeVis Medial Solutions, the move would not only reduce the time to
market of new products but also allow them to be expanded to other fields
such as the physics of magnetic resonance imaging and the modelling and
simulation of medical processes. The Bremen-based company has so far
focused on diseases of the cardio-vascular system, the brain and the lung
as well as on cancer detection and treatment.
If the company were to be converted into a Fraunhofer Institute, the
research and development partnership with MeVis Medical Solutions would be
maintained and strengthened significantly. The investment in MeVis Research
would be sold.
'The start of the negotiations with Fraunhofer is a milestone for MeVis
Medical Solutions about which we are extremely pleased,' said Dr. Carl J.G.
Evertsz, CEO of MeVis Medical Solutions. 'As a Fraunhofer Institute, MeVis
Research would sharpen Bremen’s profile as a medical engineering location,
making MeVis Medical Solutions even more attractive to its industrial
partners and employees. Contracts from the industrial sector are
indispensable for Fraunhofer Institutes. This would be a win-win situation
in which we, as the most important industrial partner of MeVis Research,
would clearly benefit from the company’s increased innovation power.
Professor Dr. Heinz-Otto Peitgen, Managing Director of MeVis Research and
Supervisory Board Chairman of MeVis Medical Solutions, also welcomes the
start of the negotiations: 'A study by the Federal Ministry for Education
and Research has revealed that products that are less then two years old
generate over 50 percent of the sales revenues in the medical engineering
sector. Should MeVis Research be given the status of a Fraunhofer
Institute, the company would establish itself as a leading European
research and development centre in the field of software support for
image-based medical diagnostics and therapy and launch more innovations
more quickly in the world market in cooperation with MeVis Medical
Solutions. This would give MeVis Medical Solutions access to a source of
expertise that is unparalleled throughout the world.'
Company Contact:
MeVis Medical Solutions AG
Dr. Olaf Sieker, Finanzvorstand
Tel: +49 421 22495-36
E-mail: olaf.sieker@mevis.de
Press and Investor Relations:
HOSCHKE & CONSORTEN Public Relations GmbH
Fabian Lorenz, Grit Pauli
Tel: +49 40 3690 50-56 / -31
E-mail: f.lorenz@hoschke.de; g.pauli@hoschke.de
(c)DGAP 06.03.2008
---------------------------------
Language: English
Issuer: MeVis Medical Solutions AG
Universitätsallee 29
28359 Bremen
Deutschland
Phone: +49 421 330 74-0
Fax: +49 421 330 74-50
E-mail: office.mms@mevis.de
Internet: http://www.mevis.de
ISIN: DE000A0LBFE4
WKN: A0LBFE
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Stuttgart, München, Düsseldorf
End of News DGAP News-Service
---------------------------------
Alliance
MeVis Research to receive 11 million Euro from federal state of Bremen
Corporate News transmitted by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
------------------------------------
MeVis Research to receive 11 million Euro from federal state of Bremen:
Minority investment of MeVis Medical Solutions in talks with Fraunhofer
Bremen, March 6, 2008.
has announced that its R&D partner, the charitable MeVis Research GmbH, is
in talks about a conversion into a Fraunhofer Institute. The accession to
the Fraunhofer-Gesellschaft would allow MeVis Research to double its
research and development activities within just a few years, expand it to
other areas of research and thus increase its attractiveness as an R&D
partner of MeVis Medical Solutions.
The company’s majority shareholder, the federal state of Bremen, yesterday
decided to provide the charitable MeVis Research with additional R&D funds
in an amount of EUR 11 million from the European Fund for Regional
Development. The City has thus paved the way for negotiations with
Fraunhofer-Gesellschaft. If the outcome is positive, MeVis Research, of
which MeVis Medical Solutions currently holds 25.1 percent, would be
admitted to the leading European organisation for applied research. The
additional funds would be used to almost double the number of employees
from today’s 50 in the coming years and to start numerous new research
projects.
As a member of Fraunhofer-Gesellschaft, MeVis Research would have access to
all resources, technologies and networks. Fraunhofer-Gesellschaft has an
annual budget totalling approx. EUR 1.3 billion. The society with its
current 56 organisations is a partner to technology companies and engages
in contractual research in all engineering subjects. From the point of view
of MeVis Medial Solutions, the move would not only reduce the time to
market of new products but also allow them to be expanded to other fields
such as the physics of magnetic resonance imaging and the modelling and
simulation of medical processes. The Bremen-based company has so far
focused on diseases of the cardio-vascular system, the brain and the lung
as well as on cancer detection and treatment.
If the company were to be converted into a Fraunhofer Institute, the
research and development partnership with MeVis Medical Solutions would be
maintained and strengthened significantly. The investment in MeVis Research
would be sold.
'The start of the negotiations with Fraunhofer is a milestone for MeVis
Medical Solutions about which we are extremely pleased,' said Dr. Carl J.G.
Evertsz, CEO of MeVis Medical Solutions. 'As a Fraunhofer Institute, MeVis
Research would sharpen Bremen’s profile as a medical engineering location,
making MeVis Medical Solutions even more attractive to its industrial
partners and employees. Contracts from the industrial sector are
indispensable for Fraunhofer Institutes. This would be a win-win situation
in which we, as the most important industrial partner of MeVis Research,
would clearly benefit from the company’s increased innovation power.
Professor Dr. Heinz-Otto Peitgen, Managing Director of MeVis Research and
Supervisory Board Chairman of MeVis Medical Solutions, also welcomes the
start of the negotiations: 'A study by the Federal Ministry for Education
and Research has revealed that products that are less then two years old
generate over 50 percent of the sales revenues in the medical engineering
sector. Should MeVis Research be given the status of a Fraunhofer
Institute, the company would establish itself as a leading European
research and development centre in the field of software support for
image-based medical diagnostics and therapy and launch more innovations
more quickly in the world market in cooperation with MeVis Medical
Solutions. This would give MeVis Medical Solutions access to a source of
expertise that is unparalleled throughout the world.'
Company Contact:
MeVis Medical Solutions AG
Dr. Olaf Sieker, Finanzvorstand
Tel: +49 421 22495-36
E-mail: olaf.sieker@mevis.de
Press and Investor Relations:
HOSCHKE & CONSORTEN Public Relations GmbH
Fabian Lorenz, Grit Pauli
Tel: +49 40 3690 50-56 / -31
E-mail: f.lorenz@hoschke.de; g.pauli@hoschke.de
(c)DGAP 06.03.2008
---------------------------------
Language: English
Issuer: MeVis Medical Solutions AG
Universitätsallee 29
28359 Bremen
Deutschland
Phone: +49 421 330 74-0
Fax: +49 421 330 74-50
E-mail: office.mms@mevis.de
Internet: http://www.mevis.de
ISIN: DE000A0LBFE4
WKN: A0LBFE
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Stuttgart, München, Düsseldorf
End of News DGAP News-Service
---------------------------------
Kurs- und weitere Informationen zum Thema:
MeVis Medical Solutions AG
Aktuelle Diskussionen zum Thema:
MeVis Medical Solutions AG (02.08.09)
Aktuelle Nachrichten zum Unternehmen:
MeVis Medical Solutions gibt W. (23.07.10)
MeVis in der Verlustzone (18.05.10)
MeVis Medical Solutions: Strategi. (18.01.10)
MeVis Medical Solutions meldet . (07.09.09)
MeVis Medical Solutions planmäß. (31.03.09)
Alle Nachrichten zum Unternehmen
Aktuelle Analysen zu den Unternehmen:
MeVis Medical Solutions AG
Weitere Meldungen
| 06.03 | DGAP-News: ICP Solar Te. |
| 06.03 | DGAP-DD: Softing AG de. |
| 06.03 | DGAP-DD: Softing AG en. |
| 06.03 | DGAP-News: Solar˛ AG |
| 06.03 | DGAP-News: MeVis Medic. |
| 06.03 | DGAP-News: MeVis Medic. |
| 06.03 | DGAP-News: Tiger Resour. |
| 06.03 | DGAP-News: Triangle Petr. |
| 06.03 | DGAP-News: Triangle Petr. |
| 06.03 | DGAP-News: Horus AG |
| 06.03 | DGAP-DD: Bien-Zenker A. |
| 06.03 | DGAP-News: Krones AG . |
| 06.03 | DGAP-News: Krones AG . |
| 06.03 | DGAP-News: Tiger Resour. |
| 06.03 | DGAP-News: Nilam Resour. |
| 06.03 | DGAP-News: Hamburger H. |
| 06.03 | DGAP-News: Hamburger H. |
| 06.03 | DGAP-News: alstria office. |
| 06.03 | DGAP-News: alstria office. |
| 06.03 | DGAP-News: Deutsche Po. |
| 06.03 | DGAP-News: Deutsche Po. |
| 05.03 | DGAP-DD: Archer Daniels . |
| 05.03 | DGAP-DD: Archer Daniels . |
| 05.03 | DGAP-DD: Archer Daniels . |
| 05.03 | DGAP-DD: Archer Daniels . |
| 05.03 | DGAP-News: Solar Millenni. |
| 05.03 | DGAP-News: Solar Millenni. |
| 05.03 | DGAP-DD: Deutsche Börse. |
| 05.03 | DGAP-DD: Deutsche Börse. |
| 05.03 | DGAP-DD: Deutsche Börse. |
Umfrage
Was halten Sie von den Thesen Thilo Sarrazins?
03.05.10 
